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ABSTRACT
The Hippo kinase pathway is emerging as a conserved signaling pathway that is 
essential for organ growth and tumorigenesis. Recently, we reported that the ubiquitin 
E3 ligase ITCH negatively regulates LATS1, thereby increasing YAP activity, which 
leads to increased cell proliferation and decreased apoptosis. Here, we investigated 
the role of ITCH in breast tumorigenesis. In particular, we show that ITCH enhances 
epithelial-to-mesenchymal transition (EMT) through boosting YAP oncogenic function. 
By contrast, a point mutation in the catalytic domain or WW1 domain of ITCH abolished 
its EMT-mediated effects. Furthermore, while overexpression of ITCH expression in 
breast cells is associated with increased incidence of mammary tumor formation and 
progression, its knockdown inhibited breast cancer cell tumorigenicity and metastasis. 
Importantly, YAP knockdown was able to attenuate ITCH pro-tumorigenic functions. 
Lastly, we found that ITCH expression is significantly upregulated in invasive and 
metastatic breast cancer cases and is associated with worse survival. Together, our 
results reveal that ITCH pro-tumorigenic functions in breast cancer are mediated, at 
least in part, through inactivation of the Hippo tumor suppressor pathway.
INTRODUCTION
The Hippo kinase pathway is emerging as 
a conserved signaling pathway that controls cell 
proliferation, apoptosis, contact inhibition, cell migration, 
cell differentiation, stem cell self-renewal, genetic 
stability, and epithelial-to-mesenchymal transition 
(EMT). Because it plays such versatile roles in cellular 
and tissue homeostasis, the Hippo signaling pathway 
appears to be essential for organ growth and homeostasis 
and its impairment leads to tissue overgrowth and tumor 
development and metastasis of different cancer types 
[1–3]
The core of the Hippo pathway is composed of a 
kinase cascade that includes MST1/2 serine/threonine 
kinase (ortholog of Hpo in D. melanogaster), WW45 
scaffold protein (Sav), MOB (Mats) and LATS1/2 
kinases (Wts). Activation of the core cascade leads to 
phosphorylation of YAP [4–6] (Yki in flies) and TAZ [7]. 
Phosphorylation of these oncoproteins leads to a complex 
formation between YAP or TAZ and 14-3-3 or to their 
β-TRCP-dependent proteasomal degradation [6, 8]. Both 
of these mechanisms prevent YAP and TAZ translocation 
to the nucleus and binding to TEAD transcription factors, 
thereby inhibiting transcription of downstream target 
genes implicated in proliferation, anti-apoptosis and EMT 
[9]. The Hippo pathway is activated mainly through the 
activation of its kinase cascade, which can be triggered 
by different upstream proteins such as Kibra–Expanded–
Merlin complex in D. melanogaster; and KIBRA, WILLIN 
and NF2, in mammals [1, 2, 10]. Other proteins capable of 
activating the core cascade of the Hippo pathway include 
the apicobasal cell polarity (ABCP) proteins, including 
mammalian Scribble (SCRIB) [1, 11, 12] and G-protein 
coupled receptors that are capable of activating LATS1/2 
independent of MST1/2 [13].
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Although the main mechanism in the regulation 
of the Hippo pathway is through activating its core 
kinases, other independent factors are also involved in 
its regulation. These mechanisms include sequestering 
the downstream effectors YAP and TAZ in the cytoplasm 
by different proteins such as the cell junction proteins 
angiomotin (AMOT) [14–16] and α-catenin [17]. Another 
mechanism that was shown to regulate the Hippo pathway 
function is the regulation of the abundance of numerous 
Hippo pathway components by various E3 ligases 
[18–20]. Indeed, two reports have recently shown that 
E3 ligase ITCH ubiquitinates LATS1 and mediates its 
proteasomal degradation [21]. This was accompanied by 
YAP accumulation and translocation into the nucleus thus 
phenocopying YAP activation [21]. ITCH is an ubiquitin 
E3 ligase that belongs to the NEDD4-like family of E3 
ubiquitin ligases. ITCH contains 4 WW domains, known 
to associate with PPxY containing targets, conferring 
substrate specificity, and a HECT-type ligase domain 
providing the catalytic E3 activity [22]. ITCH was 
originally identified as a gene disrupted in the non-agouti–
lethal 18H or Itchy mice that suffer from severe immune 
and inflammatory defects [23, 24]. A number of ITCH 
substrates that have been implicated in tumorogenesis and 
chemosensitivity have been identified, including c-Jun 
[25, 26], p73 [27], p63 [28], and ErbB4 [29].
In the current work, we dissected the role of ITCH 
in breast tumorigenesis. In particular, we show that 
ITCH enhances EMT, mammary tumor formation and 
metastasis through boosting YAP oncogenic function. 
Furthermore, ITCH knockdown inhibits breast cancer cell 
tumorigenicity and invasiveness, both in vitro and in vivo. 
Importantly, we found that ITCH levels are significantly 
increased in invasive and metastatic breast cancer samples.
RESULTS
ITCH overexpression induces a tumorigenic 
phenotype in MCF10A
We have recently shown that ITCH targets LATS1 
for degradation and inhibits the function of the Hippo 
pathway [21]. To further investigate the role of ITCH in 
breast tumorigenesis and progression, we overexpressed 
either the wild type (wt), or the first WW domain (WFPA) 
or the catalytic domain (C830A) mutants ITCH in the 
immortalized mammary gland epithelial cells, MCF10A, 
using lentiviral vectors (Fig. 1A). To test the effect of 
the different ITCH constructs on endogenous LATS1 
levels, we analyzed LATS1 protein levels in the different 
ITCH clones using immunoblot analysis. As shown in 
Fig 1A and Fig S1A, only wt ITCH was able to reduce 
endogenous LATS1 levels. Since LATS1 determines 
YAP phosphorylation levels and transactivation function, 
we analyzed ITCH clones for phospho-YAP (p-YAP) 
expression and YAP target genes, CTGFβ and CYR61. 
Only wt ITCH overexpression reduced p-YAP levels 
(Fig 1A) and increased YAP target gene expression 
(Fig 1B). Compared to C830A, which showed sometimes 
a dominant negative effect, a point mutation in the first 
WW domain of ITCH (ITCH-WFPA) displayed a milder 
effect on both YAP phosphorylation (Fig 1A, S1A) and 
YAP target gene expression (Fig 1B). To demonstrate 
the effect of the different ITCH constructs on breast cell 
phenotypes, we tested cell proliferation using XTT test, 
cell survival using colony formation assay or by culturing 
the cells in three dimensions (3D) in growth factor 
depleted Matrigel. Our results demonstrate that only wt 
ITCH was able to increase cell proliferation (Fig 1C) and 
cell survival (Fig 1D, E). These results suggest that ITCH 
enhances cell growth of MCF10A cells.
ITCH supports a mesenchymal growth 
phenotype of MCF10A cells
The Hippo pathway controls proper tissue growth 
and homeostasis, and its deregulation promotes EMT of 
cultured cells, a hallmark of metastatic cancer cells. To 
examine the effect of ITCH on breast cancer progression 
in the context of the Hippo pathway, we tested the effect 
of different ITCH constructs on MCF10A cell morphology 
and mammosphere formation. When cultured in two 
dimensions (2D), control unmanipulated MCF10A cells 
tend to form well-circumscribed colonies even before 
filling the culture plates. In contrast, we found that 
overexpression of wt ITCH changes MCF10A cell 
morphology to a more mesenchymal phenotype precluding 
normal colony formation (Fig 2A). Both ITCH-WFPA and 
ITCH-C830A expression didn’t affect cell morphology 
(Fig 2A).
When cultured in 3D, MCF10A cells are able to 
form very well organized mammospheres that recapitulate 
mammary cell growth in vivo. Our results revealed that 
overexpression of wt ITCH disrupt the formation of 
mammospheres, with mild versus no effect of WFPA and 
C830A ITCH constructs, respectively (Fig 2B). To further 
elucidate whether this change of breast cell morphology 
is accompanied with a more invasive potential, we tested 
the ability of the different MCF10A ITCH clones to invade 
Matrigel coated filters in a Boyden chamber Matrigel 
invasion assay. As shown in Fig 2C & D, wt ITCH 
expressing MCF10A cells displayed enhanced invasion 
ability relative to control or ITCH-WFPA cells. The ITCH-
C830A expressing cells exhibited reduced invasion ability 
as compared to control cells again suggesting a dominant 
negative effect. To explain these pro-mesenchymal 
changes, we tested the effect of different ITCH constructs 
on levels of the epithelial marker E-cadherin and the 
mesenchymal marker Vimentin. First, we checked the 
expression levels of LATS1, p-YAP and total YAP to 
show that ITCH affects LATS1 expression and function. 
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Our results show that only wt ITCH drastically decreases 
the expression of LATS1 and thus p-YAP while increasing 
total YAP levels indicating that only wt ITCH inhibits 
the Hippo pathway function (Fig 2E & S1B). Next we 
examined the effect of ITCH on EMT markers. While wt 
ITCH reduced E-cadherin and increased Vimentin levels, 
WFPA and C830A expressing cells were unable to do so 
(Fig 2E & S1B). These results suggest that ITCH enhances 
EMT and invasion potential of MCF10A cells.
ITCH expression enhances MCF10A cell 
tumorigenesis in vivo
After demonstrating the effects of ITCH on breast 
cell tumorigenicity in vitro, we set to test its effect on these 
cells in vivo. To prove that ITCH plays a role in breast 
tumorigenesis in vivo, we injected ITCH overexpressing 
MCF10A cells into the mammary fat pad (MFP) of Nod-
SCID female mice. Two months later, we observed that 
ITCH expression in MCF10A cells didn’t lead to tumor in 
these mice (data not shown) suggesting that ITCH alone is 
not enough to transform MCF10A cells. To have a proper 
model to study the role of ITCH in vivo, we overexpressed 
the different ITCH constructs mentioned above in H-RAS 
transformed MCF10A cells (MCF10A-RAS cells, [30]). 
First, we characterized the tumorigenic potential of these 
cells in vitro. We tested their survival and tumorigenicity, 
by colony formation and soft agar assays, respectively. 
We observed that more colonies were formed in wt ITCH 
overexpressing MCF10A-RAS cells, as compared to 
Figure 1: Effect of ITCH constructs overexpression in MCF10A cells. (A) Immunoblot analysis showing the effect of 
overexpressing different ITCH constructs in MCF10A cells on LATS1 and pYAP levels upon 50% and 100% cell culture confluency. 
(B) Real time PCR showing the effect of different ITCH constructs on YAP target genes in 50% cell confluent culture. (C) XTT cell 
proliferation assay results showing the effect of ITCH manipulation on MCF10A growth rate. D & E. Colony formation (D) and 3D culture 
assay (E) experiments, respectively, showing the effect of ITCH manipulation on MCF10A cell survival. In all figures, error bars represent 
the standard deviation of at least three different biological experiments done in triplicates. The statistical significance was measured by 
calculating the p values for all experiments related to EV; * indicates P value <0.05, **P value < 0.01, ***P value <0.001.
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cells overexpressing either the WFPA or C830A mutant 
ITCH constructs, indicating a higher survival rate of 
these cells (Fig 3A). In a similar manner, soft agar assays 
clearly indicated that wt ITCH overexpression results 
in MCF10A-RAS cells having a growth advantage over 
control cells or cells over expressing WFPA or C830A 
ITCH (Fig 3B & S2A).
After characterizing these cells in vitro, we 
tested their tumorigenic potential in vivo. Cells were 
orthotopically injected into MFP of Nod-SCID mice and 
tumor formation was monitored. While no tumors were 
observed in MCF10A-ITCH cells, clones overexpressing 
both RAS and ITCH (RAS/ITCH) developed accelerated 
tumors, as early as one week post-injection. These 
mice had to be sacrificed one month after cell injection 
due to big tumors’ formation. In comparison, cells over 
expressing RAS/ITCH-WFPA or RAS alone developed 
smaller tumors with slower growth rate (Fig 3C & 
S2B). Of note, mice injected with RAS/ITCH-C830A 
developed no tumors (Fig 3C). To confirm that ITCH 
enhances breast tumorigenesis by inhibiting the Hippo 
pathway, tumors were analyzed for YAP expression 
Figure 2: Effect of ITCH expression on EMT in MCF10A cells. (A) Morphology changes of MCF10A cells expressing either empty 
vector (EV) or different ITCH forms when cultured in 2D. Images were obtained using inverted light microscope using 100X magnification. 
(B) Mammosphere formation in 3D Matrigel cell culture of MCF10A cells. Images were obtained using inverted light microscope using 200X 
magnification. (C) Representative images of Boyden Chamber Matrigel invasion assay of MCF10A cells. (D) Quantification of invading 
cells in C. (E) Immunoblot analysis showing the effect of overexpressing different ITCH constructs in MCF10A cells on EMT markers. In 
all figures, error bars represent the standard deviation of three different biological experiments done in triplicates. The statistical significance 
was measured by calculating the p values for all experiments related to EV; * indicates P value <0.05, **P value <0.01, ***P value <0.001.
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using immunohistochemistry (IHC). We observed strong 
nuclear staining of YAP in tumors obtained from cells 
overexpressing both RAS and wt ITCH, compared to 
cells overexpressing either RAS alone or RAS with 
ITCH-WFPA mutant (Fig 3D). To further decipher 
the role of ITCH on breast cancer progression into a 
metastatic disease, we examined lungs of these mice by 
staining for p-Erk, a downstream effector of RAS. While 
tumors obtained from cells overexpressing ITCH and 
RAS together showed a strong staining of p-Erk in large 
areas of the stained lung tissues (Fig 3E), indicating the 
presence of metastatic foci, tiny or even no metastatic 
foci were observed in animals bearing tumors of RAS 
and ITCH-WFPA or RAS alone, respectively (Fig 3E, F). 
Collectively, these data demonstrate that ITCH cooperates 
with RAS to accelerate breast tumor growth in vivo.
ITCH knockdown inhibits the tumorigenic 
phenotype of MDA-MB435 breast cancer cells
Our results obtained from the overexpression system 
prompted us to test whether ITCH knockdown inhibits 
the tumorigenic phenotype of breast cancer cells. To this 
end we knocked down ITCH in the aggressive metastatic 
breast cancer cell line MDA-MB435 [31] using small 
hairpin (ShRNA) constructs expressed in lentiviral vectors. 
Figure 3: ITCH enhances tumorigenicity of H-RAS transformed MCF10A cells. (A) Quantification of cell survival rates 
as assessed by colony formation assays. (B) Quantitative presentation of soft agar assays (Fig S2A) showing cell tumorigenic potential 
following the expression of the indicated proteins. (C) Tumor growth curve of MFP tumors in Nod-SCID mice injected with MCF10A 
overexpressing the indicated proteins. (n=6mice/group). (D) IHC staining for YAP in lungs obtained from mice described in C. Brown color 
indicates positive staining while blue color of the counter stain hematoxyline indicates a negative staining. (E) IHC staining for the RAS 
downstream effector, p-Erk, on lungs obtained from mice described in C. In all figures, error bars represent the standard deviation of three 
different biological experiments done in triplicates. The statistical significance was measured by calculating the p values for all experiments 
comparing ITCH to EV, RAS/WT to ITCH or RAS; * indicates P value <0.05, **P value <0.01 , ***P value <0.001.
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After infection and selection, stable clones were generated. 
To prove successful ITCH knockdown, we tested ITCH 
protein levels in either control cells or ITCH Sh clones 
using immunoblot analysis. As shown in Fig S3A, ITCH 
Sh clones showed a significant decrease in ITCH levels 
compared to control cells. To demonstrate the effect of ITCH 
knockdown on cell proliferation and survival of MDA-
MB435 cells, we performed XTT and colony formation 
assays. As shown in Fig 4 A & B, both traits were attenuated 
by ITCH knockdown. To test whether ITCH knockdown 
can reverse the mesenchymal growth phenotype to a more 
epithelial one, we cultured ITCH Sh clones in 3D culture 
and tested their ability to form organized mammospheres. 
Indeed, ITCH Sh clones were able to form relatively more 
organized spheres compared to control cells (Fig 4C), which 
resembles a more epithelial phenotype. To further confirm 
that ITCH is a pro-invasive factor in breast cancer, we tested 
the effect of ITCH knockdown on the invasive potential of 
MDA-MB435 breast cancer cells using a Boyden chamber 
Matrigel invasion assay. Likewise, our results clearly 
demonstrated that ITCH depletion dramatically inhibits the 
invasion capability of MDA-MB435 cells (Fig 4D, S3B). 
To further dissect these phenotypes, we tested the effect of 
ITCH knockdown on levels of the mesenchymal markers 
N-Cadherin and fibronectin, using immunoblot analysis. 
Our results demonstrated that ITCH knockdown reduces 
N-cadherin and fibronectin protein levels in MDA-MB435 
cells (Fig 4E & S1C).
Figure 4: ITCH depletion inhibits MDA-MB435 breast cancer cell tumorigenic phenotypes. (A) XTT proliferation assay 
showing the effect of ITCH knockdown on cell growth rate. (B) Quantification of cell survival rates using colony formation assay. (C) Micrographs 
of 3D cell culture of MDA-MB435 cells expressing either empty vector (EV) or ITCH Sh construct. (D) Quantitative presentation of Boyden 
Chamber Matrigel invasion assay results of MDA-MB435 cells expressing either EV or ITCH Sh construct. (E) Immunoblot analysis showing 
the effect of ITCH knockdown on EMT markers in MDA-MB435 cells. (F) Tumor growth curve of control and ITCH Sh MDA-MB435 cells 
injected in the MFP of Nod-SCID mice (n=6/group). Mice were analyzed 8-weeks post injection. (G) Graphical representation of tumor weight 
described in F. It was noted that tumors developed in control cells (EV) had a significant necrotic areas. (H) Representative micrographs of 
lungs obtained from Nod-SCID mice injected orthotopically into MFP or into the tail vein (IV) with control or ITCH Sh MDA-MB435 breast 
cancer cells constitutively expressing GFP. Mice were analyzed 6-weeks post injection. (I) Quantification of macrometastatic foci number 
obtained in the lungs of mice in the MFP model; (n=6/group). (J) Quantification of macrometastatic foci number obtained in the lungs of 
mice in the IV model; (n=6/group). In all figures, except those of mice, error bars represent the standard deviation of three different biological 
experiments done in triplicates. The statistical significance was measured by calculating the p values for all experiments related to EV; * indicates 
P value <0.05, **P value <0.01, ***P value <0.001.
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ITCH knockdown attenuates MDA-MB435 
breast cancer cell metastatic potential in vivo
To further confirm that ITCH affects breast cancer 
cell tumorigenicity in vivo, ITCH-depleted MDA-
MB435 cells, which constitutively express GFP, were 
orthotopically injected in MFP of Nod-SCID mice and 
rate of tumor growth was followed. We found that ITCH 
knockdown resulted in reduced tumor volume and weight 
(Fig 4F, G) indicating that ITCH knockdown is associated 
with reduced breast cancer cell tumorigenesis.
To support our in vitro findings that convincingly 
demonstrated that ITCH enhances the invasiveness of 
breast cancer cells, we decided to test ITCH depletion 
on seeding metastasis. To this end, we first injected GFP-
labeled MDA-MB435 ITCH Sh and control cells in the tail 
vein of Nod-SCID mice and followed GFP dissemination 
in the internal organs of these mice, especially in the 
lungs. We observed that ITCH knockdown inhibited 
lung colonization compared to control cells (Fig 4H, 
lower panel &I). Since the IV model doesn’t represent 
the whole metastatic cascade, we orthotopically injected 
the same cells in MFP of mice and followed metastatic 
foci development in the lungs of these mice. When 
comparing same size primary tumors, we found that 
ITCH knockdown resulted in reduced lung metastatic foci 
formation as compared to control cells (Fig 4H, upper 
panel & J). Moreover the number of mice that developed 
lung metastasis was less upon ITCH knockdown 
(Fig S3C). These results clearly demonstrate that ITCH 
depletion inhibits breast cancer metastasis in vivo.
ITCH depletion inhibits metastatic traits of 
MDA-MB231 breast cancer cells
To confirm that the observed phenotypes of ITCH 
depletion are not cell specific, we knocked down ITCH in 
the MDA-MB231 invasive breast cancer cells. Likewise, 
ITCH knockdown in this cell line, was associated with 
reduced cell proliferation and survival, as measured 
by XTT and colony formation assays, respectively 
(Fig 5A, B) similar to ITCH depleted MDA-MB435 cells. 
In addition, ITCH depletion in these cells dramatically 
inhibited their invasion capability (Fig 5C, D). Moreover, 
ITCH knockdown in MDA-MB231 cells inhibited the 
mesenchymal growth phenotype in 3D culture settings 
(Fig 5E). To explain whether these mesenchymal 
phenotypes are related to inactive Hippo pathway, we tested 
the effect of different ITCH knockdown on the expression 
level of YAP targets, CTGFβ, CYR61 and fibronectin 
using qRT-PCR. As shown in Figure 5F, the expression 
of these YAP targets is decreased upon ITCH knockdown. 
We further examine the effect of ITCH depeletion in these 
cells in vivo. GFP-labeled MDA-MB231 ITCH Sh and 
control cells were injected in the tail vein of Nod-SCID 
mice and GFP dissemination in the lungs was assessed. We 
found that ITCH knockdown attenuated lung colonization 
compared to control cells (Fig 5G, H). Altogether, these 
results clearly demonstrate that ITCH knockdown inhibits 
MDA-MB231 breast cancer cell growth, survival and 
invasion in vitro and metastasis in vivo further confirming 
that these effects are not cell specific.
YAP knockdown rescues ITCH mediated 
phenotypes in MCF10A cells
We have previously shown that ITCH enhances 
breast tumorigenesis by negative regulation of LATS1 
[21], a key component of the Hippo pathway. This 
negative regulation of LATS1 was accompanied by 
reduced YAP activity. To further investigate the role of 
ITCH in breast carcinogenesis and to examine whether 
its function is mediated by activating YAP, we knocked 
down YAP in MCF10A-ITCH cells. To demonstrate a 
successful YAP knockdown we measured YAP mRNA 
levels using qRT-PCR. Our results indeed demonstrated 
reduced levels of YAP mRNA, indicating a successful 
YAP knockdown (Fig 6A). This reduction in YAP levels 
was accompanied by a downregulation of YAP target 
genes, CTGFβ and CYR61, confirming reduced YAP 
function as well (Fig 6A). To further confirm the effect 
of YAP knockdown on ITCH induced tumorigenicity in 
breast cells, we tested the effect of YAP knockdown on 
cell survival, using colony formation assay. While ITCH is 
capable of promoting cell survival, YAP knockdown was 
able to reverse this phenotype (Fig 6B).
To examine the consequences of YAP depletion in 
MCF10A-ITCH cells, we followed the expression of EMT 
markers by immunoblot analysis. We found that while 
ITCH overexpression leads to Vimentin upregulation and 
to E-cadherin downregulation, YAP knockdown displayed 
lower levels of Vimentin and higher levels of E-cadherin 
(Fig 6C & S1D). To demonstrate whether this effect 
on EMT related proteins would affect mammosphere 
culture of breast cells in vitro, we tested the effect of 
YAP knockdown on MCF10A-ITCH cell mammosphere 
formation. We observed that while overexpression of 
ITCH interferes with mammosphere formation and results 
in disorganized mammosphers characterized by abnormal 
bulging structures (Fig 6D second panel, arrows), YAP 
depletion was able to reverse the effect of ITCH on 
mammosphere formation to almost a normal and very 
well-circumscribed one (Fig 6D). To further investigate 
whether YAP knockdown is capable of reversing ITCH-
induced invasion potential of breast cells, we tested the 
ability of YAP knockdown to reduce the effect of ITCH 
on MCF10A cell invasion in a Boyden chamber Matrigel 
invasion assay. As shown in Fig 6E & F, YAP knockdown 
was able to rescue the effect of ITCH on MCF10A 
invasiveness.
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YAP depletion attenuates ITCH-mediated 
tumorigenicity in MCF10A cells
To complement our in vitro findings demonstrating 
that ITCH induces tumor initiation and progression by 
activating YAP with an in vivo model, we injected GFP-
labeled MCF10A-RAS/ITCH and MCF10A-RAS/ITCH/
YAP-sh cells into MFP of Nod-SCID mice and followed 
tumor development and progression. We noticed that 
YAP knockdown in these cells leads to slower tumor 
development (Fig 7A), to ~40% reduction in tumor size 
(Fig 7B) and to less lung metastatic foci formation (Fig 7C), 
as assessed by GFP immunohistochemistry staining. To 
quantify the difference in metastatic foci formation, we 
measured the expression of GFP in lungs of mice from 
control and YAP Sh groups. Our qRT-PCR results indeed 
confirmed reduced GFP expression and levels of YAP 
targets upon YAP knockdown (Fig 7D). These data further 
confirm that ITCH induces its tumorigenic phenotype by 
deregulating the Hippo pathway and limiting its negative 
effect on its oncogenic effector, YAP.
Increased ITCH protein levels correlate with 
metastatic breast cancer and worse survival.
To show the human relevance of ITCH expression 
in breast cancer, we stained tissue microarrays (TMAs) for 
ITCH and YAP using immunohistochemistry. Validation 
Figure 5: ITCH knockdown inhibits tumorigenicity of MDA-MB231 breast cancer cells. (A) XTT proliferation assay 
showing the effect of ITCH knockdown on MDA-MB231 cell growth rate. (B) Quantification of cell survival rates using colony formation 
assay. (C) Quantitative presentation of Boyden Chamber Matrigel invasion assay results of MDA-MB231 cells expressing either empty 
vector (EV) or ITCH Sh construct. (D) Representative micrographs of Boyden Chamber Matrigel invasion assay of MDA-MB231 cells 
expressing either EV or ITCH Sh construct. (E) Micrographs of 3D cell culture of MDA-MB231 cells expressing either EV or ITCH Sh 
construct. (F) Real time PCR showing the effect of ITCH knockdown on YAP target genes. (G) Representative micrographs of lungs 
obtained from Nod-SCID mice injected into the tail vein (IV) with control or ITCH Sh MDA-MB231 breast cancer cells constitutively 
expressing GFP. Mice were analyzed 4-weeks post injection. (H) Graphical representation of the number of metastatic foci obtained in the 
lungs of mice in the IV model; n=6/group. In all figures, error bars represent the standard deviation of three different biological experiments 
done in triplicates. The statistical significance was measured by calculating the p values for all experiments related to EV. (*P value <0.05, 
**P value <0.01, ***P value <0.001).
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and specificity of the immunohistochemical staining 
is shown in Fig S4. Our data show that while low 
ITCH levels were detected in normal, hyperplastic 
and intraductal carcinoma tissue samples, high ITCH 
expression levels were seen in infiltrating or invasive 
ductal carcinoma samples as well as in samples that 
metastasized to secondary organs (Fig 8A). Representative 
images of the stained tissues are shown in Fig S5A. In fact, 
high expression of ITCH was observed in the majority 
(64%) of advanced stages of breast cancer cases (Fig S5B). 
As for YAP staining, normal and  pre-neoplastic lesions 
showed variable expression (Fig 8B). Forty one percent 
of advanced stages of breast cancer, including infiltrating 
or invasive ductal carcinoma as well as metastasis, 
displayed high YAP levels (Fig S5B). Interestingly, we 
found a positive correlation between ITCH and YAP levels 
in about 70% of these samples (Fig S5C). To elucidate 
whether ITCH is expressed at equal frequency in the 
different breast cancer subtypes, we analyzed our TMA 
for the distribution of ITCH in ER+, HER2+, and triple-
negative invasive breast cancers. However, no inverse 
correlation was found between ITCH expression and the 
Figure 6: YAP knockdown rescues ITCH-mediated EMT phenotypes in MCF10A cells. (A) qRT-PCR results showing 
successful YAP mRNA knockdown accompanied with downregulation of YAP target gene mRNA in 50% cell confluent culture. (B) Colony 
formation assay results showing the effect of YAP silencing on MCF10A cells overexpressing ITCH. (C) Immunoblot analysis showing 
the effect of YAP knockdown on EMT markers induced by ITCH overexpression. (D) 3D culture of MCF10A cells expressing either 
ITCH alone or ITCH and YAP Sh construct. Arrows point to abnormal structures in the mammospheres. (E) Representative pictures of the 
invading cells of the different indicated clones in Boyden chamber Matrigel invasion assy. (F) Quantification of Boyden chamber Matrigel 
invasion assay results in E. In all figures, error bars represent the standard deviation of three different biological experiments done in 
triplicates. The statistical significance was measured by calculating the p values for all experiments comparing ITCH to EV, ITCH-YAP-Sh 
to ITCH. * indicates P value <0.05, **P value <0.01 , ***P value <0.001.
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distinct groups, likely due to the low number of cases in 
each category (data not shown).
To explore the prognostic value of ITCH expression 
in breast cancer, we evaluated mRNA expression of ITCH 
from publicly gene expression data set using the Kaplan-
Meier Plotter resource [32]. Patients were divided into 
two groups (high and low ITCH expression) based on the 
Affymetrix 217094_s_at probe. These groups were then 
compared using the relapse-free survival (RFS), overall 
survival (OS), distant metastasis-free survival (DMFS), 
and post-progression survival (PPS). As shown in Fig 8C, 
Kaplan-Meier analysis revealed that high expression of 
ITCH was associated with shorter RFS (n=3455), shorter 
OS (n=1115), shorter DMFS (n=1609) and shorter PPS 
(n=351) in breast cancer patients. Interestingly, we also 
identified a significant association between high ITCH 
expression and shorter RFS in positive lymph node 
patients (n=936) (Fig 8D). Next, we tested the correlation 
between ITCH expression and it’s prognostic value in the 
different breast cancer subtypes, basal, luminal A, luminal 
B and HER+. As shown in Fig 8E, Kaplan-Meier analysis 
revealed that high expression of ITCH is associated with 
shorter RFS (n=1678) and shorter OS (n=504) in luminal 
A breast cancer patients. No correlation was revealed in 
basal, Luminal B, and HER+ patients (data not shown). 
These data confirm that ITCH is overexpressed in 
metastatic breast cancer lesions and that its expression is 
associated with worse survival.
Figure 7: Effect of YAP knockdown on tumor progression in MCF10A cells overexpressing ITCH. (A) Tumor growth 
rate curve showing the effect of YAP knockdown on tumor growth; (n=6mice/group). (B) Quantitative presentation of the effect of YAP 
knockdown on tumor volume. (C) Representative micrographs of lungs obtained from Nod-SCID mice injected orthotopically into MFP 
with ITCH overexpressing cells or cells overexpressing both ITCH and YAP Sh. Upper panels show metastatic foci of cells constitutively 
overexpress GFP while lower panels show IHC of lungs using anti-GFP. (D) Relative mRNA expression levels of the indicated genes 
on RNA obtained from lungs. In all figures, error bars represent the standard deviation of the same experiment made in triplicates. The 
statistical significance was measured by calculating the p values for all experiments comparing MCF10A Ras/ITCH to MCF10A Ras/ITCH/
YAPsh. * indicates P value <0.05, **P value <0.01 , ***P value <0.001.
Oncotarget11www.impactjournals.com/oncotarget
DISCUSSION
In the current study we investigated the pro-
tumorigenic function of ITCH in breast cancer. In particular, 
we demonstrate that ITCH enhances EMT through 
enhancing YAP oncogenic function. By contrast, a point 
mutation in the catalytic domain or WW1 domain of ITCH 
almost abolished its EMT-mediated effects. Furthermore, 
while overexpression of ITCH in breast cancer cells is 
associated with increased incidence of mammary tumor 
formation in vivo, its knockdown inhibited breast cancer 
cell tumorigenicity and reduced their metastatic potential, 
both, in vitro and in vivo. Mechanistically, we show that 
these ITCH-induced pro-tumorigenic phenotypes can 
be rescued, at least in part, by depleting YAP, further 
confirming that ITCH regulates the Hippo pathway. To 
demonstrate the human relevance of our findings, we tested 
ITCH expression in human breast cancer tissue samples and 
found that ITCH expression is significantly upregulated in 
invasive and metastatic breast cancer cases.
Figure 8: Prognostic significance of ITCH expression in different breast cancer subtypes. (A) IHC scoring of ITCH protein 
in different breast cancer cases. The staining scores were as follows; 0= no staining, 1= weak staining, 2= moderate staining, 3= strong 
staining, 4= very strong staining. (B) IHC scoring of YAP protein in different breast cancer cases. The staining scores were as follows; 
0= no staining, 1= weak staining, 2= moderate staining, 3= strong staining. C-E. Kaplan-Meier survival curves obtained from Kaplan-Meier 
Plotter recourse showing the correlation between ITCH mRNA expression and relapse-free survival (RFS), overall survival (OS), distant 
metastasis-free survival (DMFS), and post-progression survival (PPS) in breast cancer cohort (C); RFS in lymph node positive breast 
cancer samples (D); RFS and OS in Luminal A breast cancer patients (E).
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Our findings clearly indicate that ITCH positively 
regulates proliferation, survival and invasion of breast 
cancer cells. ITCH depletion in two metastatic breast 
cancer cells hampers their cell proliferation and survival, 
inhibits invasion ability and attenuated tumor growth and 
metastatic potential. These findings indicate that ITCH 
can regulate different steps of the metastatic cascade 
including early steps such as invasion (EMT) and later 
ones as survival and colonization (MET). Detailed 
characterization of ITCH-mediated phenotypes both in 
vitro, using Gelfoam cultures [33], and in vivo, using high 
quality GFP tumor and cellular imaging [33–37], shall 
be required to further decipher ITCH protumorigenic 
functions in breast cancer progression and metastasis.
Several studies have confirmed ITCH and other E3 
ubiquitin ligases ability of regulating the Hippo pathway. 
For example, it has been recently shown that WWP1 and 
NEDD4 negatively regulate LATS1 by promoting its 
proteasomal degradation [18, 19]. Negative regulation of 
LATS1 function was shown to mediate WWP1-induced 
breast cancer cell proliferation [19]. It has also been 
demonstrated that NEDD4, NEDD4-2 and ITCH mediate 
polyubiquitination of AMOT/p130 [38], a member of 
AMOT family of proteins (AMOT/p130, AMOTL1 and 
AMOTL2) and resulted in regulating the downstream 
effectors of the Hippo pathway YAP and TAZ [15, 16, 39]. 
Intriguingly, ITCH appears to have dual antagonistic 
regulatory functions on the Hippo pathway. While we and 
others clearly demonstrated that ITCH negatively regulates 
the Hippo pathway by targeting LATS1 for degradation, 
Adler et al. [40] showed that AMOT/p130 directs ITCH 
towards the induction and inhibition of YAP1 and LATS1 
degradation, respectively. Intriguingly when co-expressed 
together, ITCH and AMOT/p130 were shown to suppress 
cell growth, confirming an anti-tumor effect of ITCH. 
These findings might indicate that the effect of ITCH on 
the Hippo pathway is context dependent and that its E3 
ligase function is tightly regulated. Future investigation 
will be required to uncover the role of ITCH activity in 
the different contexts.
Previously, we showed that ITCH interacts with 
LATS1 mainly through its first WW domain (WW1). Here 
we show that a point mutation in WW1 of ITCH is enough 
to abrogate ITCH induced pro-tumorigenic phenotypes 
in vitro and in vivo. Many WW domain-containing 
proteins have more than one WW domain and, usually, 
the functions of the different WW domains in the same 
protein are not redundant. Rather, WW domain-containing 
proteins may utilize alternative combinations of WW 
domains to bind different partners. For example, ITCH 
was recently shown to interact with AMOT/p130 via its 
WW1 and WW2 and not WW3 and WW4 [41]. Moreover, 
it has been shown that ITCH binds to p73α through its 
WW2 domain [42]. ITCH by itself can also be a target 
of WW domain interactions. Recently, we reported that 
ITCH, via its LPxY motifs, interacts with WW-domain 
containing protein, WWOX [43]. Interestingly, ITCH 
mediates K63-linked polyubiquitination of tumor 
suppressor WWOX that leads to WWOX nuclear 
localization and increased cell death. The choice between 
K48 and K63 seems to be another factor that dictates the 
effect of ITCH on its substrates and adds to the complexity 
of understanding the roles of ITCH in different cellular 
contexts. While K48-linkages are mostly associated 
with commitment for proteasomal degradation, K63-
linked polyubiquitination plays established roles in DNA 
damage repair, protein kinase activation and trafficking 
[44]. Indeed, compelling evidence have recently shown 
that ITCH mediated K63-linked polyubiquitination of 
WWOX is associated with its novel function in the DNA 
damage response [45]. It is thus clear that ITCH could 
exert various functions depending on its substrate and on 
the stimuli that activate it.
YAP and TAZ are the most known downstream 
effectors of the Hippo pathway that execute and regulate 
the pathway responses to different cellular processes 
related to tumorigenesis [46]. Inactivation of the Hippo 
pathway and thus YAP hyperactivation results in 
higher proliferative rates in different tissues [6, 17, 47], 
enhanced cell survival and resistance to death induced by 
chemotherapy and anoikis [48–50], maintenance of a stem 
cell phenotype [51, 52] and EMT and metastasis [5, 49, 
53]. Interestingly, our work demonstrate that the invasive 
properties induced by ITCH overexpression can be rescued 
by YAP depletion, indicating that, at least in part, ITCH 
inactivates the Hippo pathway function by increasing 
YAP function. These findings are in agreement with our 
previous findings demonstrating that ITCH overexpression 
leads to LATS1 degradation and less YAP phosphorylation 
and thus its hyperactivation [21]. Future work shall 
address whether LATS1-resistant mutants that are unable 
to be ubiquitinated by ITCH are protumorigenic.
ITCH is overexpressed in different cancer types [54] 
and in our present work, we show that ITCH is highly 
expressed in breast cancer samples especially in advanced 
metastatic cases and that these high levels correlate 
with high YAP expression levels, consistent with recent 
observations showing high YAP1 expression in multiple 
cancer subtypes [48, 55]. Furthermore, high ITCH mRNA 
has a prognostic value as it correlates with worse survival 
of luminal A breast cancer patients. These results indicate 
that ITCH might function as a pro-tumorigenic factor 
that supports a more aggressive type of breast carcinoma 
at least in part by modulating YAP function, the most 
downstream effector of the Hippo pathway.
MATERIALS AND METHODS
Cell culture and transient transfection
HEK293, MDA-MB435 and MDA-MB231 cells 
were grown in RPMI, supplemented with 10% fetal 
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bovine serum (Gibco, NY), glutamine, and penicillin 
streptomycin (Beit Haemek, Israel). MCF-10A cells were 
grown in DMEM/F12 supplemented with 5% donor horse 
serum, 20 ng/ml epidermal growth factor (EGF), 10 μg/
ml insulin, 0.5 μg/ml hydrocortisone, 100 ng/ml cholera 
toxin, and antibiotics. Overexpression of proteins was 
achieved by transient transfections using Mirus TransLTi 
(Mirus Bio LLC, Madison, WI).
Immunoblot Analysis
Cells were lysed by using Nonidet P-40 lysis buffer 
containing 50 mM Tris (pH 7.5),150 mM NaCl, 10% 
glycerol, 0.5% Nonidet P-40, and protease inhibitors. 
Western blotting was performed under standard conditions. 
Antibodies used were monoclonal anti-E. Cadherin and N. 
Cadherin (BD Biosciences, Lexington, KY), polyclonal 
anti-LATS1 (Bethyl, Montgomery, TX), phospho-
YAPS127 and anti-YAP (Cell Signaling, Danvers, MA), 
Monoclonal anti-GAPDH (Calbiochem), polyclonal anti-
fibronectin (Sigma Aldrich), monoclonal anti-Vimentin and 
monoclonal anti-ITCH (BD Biosciences, Lexington, KY).
RNA extraction and reverse transcription-PCR 
and Real Time PCR
Total RNA was prepared using the TRI reagent 
(Sigma Aldrich) as described by the manufacturer. One 
microgram of RNA was used for cDNA synthesis using 
First-Strand cDNA Synthesis kit (Bio-Rad, Hercules, CA). 
Quantitative real-time PCR was performed using Power 
SYBR Green PCR Master Mix (Applied Biosystems, 
Foster City, CA). All measurements were performed in 
triplicate and standardized to the levels of GAPDH.
In vivo tumorigenesis
1×106 cells were suspended in 20μ l of 30% Matrigel 
cell culture medium and kept on ice until injection time. 
Cell suspension was then injected in the mammary fat pad 
of the abdominal mammary gland of Nod-SCID mice. 
Later, both primary tumors and other organs, including 
lungs, were excised for further analysis. For Intravenous 
injection, 1×106 cells were suspended in 200μ l PBS and 
injected slowly into the tail vein. 8 weeks later animals 
were scarified, and lungs were excised and photographed 
with dissecting fluorescent microscope.
Immunohistochemistry
Paraffin-embedded tissue sections or tissue 
microarray slides (US Biomax, Inc) were deparaffinized 
and rehydrated. Antigen retrieval was performed in 10 mM 
sodium citrate buffer pH 6.0 using pressurized chamber 
for 2.5 min. Endogenous peroxidase was blocked with 3% 
H2O2 for 10 min. The sections were then incubated with 
blocking solution (CAS Block, Invitrogen, Grand Island, 
NY) for 30 min to reduce non-specific binding followed 
by incubation with the primary antibody: monoclonal 
anti-ITCH antibody (Sigma Aldrich) [dilution of 1:100], 
anti-YAP (Epitomics) [dilution of 1:200], or anti-pErk 
(Cell signaling) [dilution of 1:100] in humidity chamber for 
overnight incubation. Slides were subsequently incubated 
with horseradish peroxidase-conjugated antibody for 
30 min. The enzymatic reaction was detected in a freshly 
prepared 3,3 diamminobenzidine tetrahydrochloride using 
DAKO Liquid DAB Substrate-Chromogen (Carpinteria, 
CA) Solution for several minutes at room temperature. 
The sections were then counterstained with hematoxylin. 
Negative controls includes slides that were incubated with 
primary antibody alone without secondary antibody or 
slides that were incubated with secondary antibody alone 
without primary antibody. The staining scores were as 
follows; 0=No staining, 1=Weak staining, 2= Moderate 
staining, 3=Strong staining, 4=Very strong staining. 
Representative pictures of the negative and positive 
controls and the scoring system are shown in Fig S4 and 
S5A, respectively.
Proliferation, Colony Formation and 
Matrigel invasion assays and 3D culture 
of MCF-10A cells.
These tests were done as described previously [21].
Statistical Analysis
Results were expressed as mean ± SD. Student 
t-test used to compare values of test and control samples. 
P < 0.05 indicated significant difference.
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